Luminex, Merck to develop companion Dx for Alzheimer's drug

03/14/2013 | GenomeWeb Daily News (free registration) · Fox Business

Luminex and Merck & Co. have entered a partnership to develop a companion test for the latter's MK-8931, an investigational drug for Alzheimer's disease. The test will be used to screen patients for a clinical trial of MK-8931. The assay will assess levels of two potential disease biomarkers in cerebrospinal fluid samples from patients who demonstrate mild cognitive impairment.

View Full Article in:

GenomeWeb Daily News (free registration) · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY